Altshuler Shaham’s Redhill Biopharma RDHL Stock Holding History

Altshuler Shaham’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27	Closed	-$3.72K	–	451
2022 Q4	$3.72K	Buy	+27	New	+$11.7K	﹤0.01%	405
2018 Q4	–	Hold	0	–	-$1K	–	297
2018 Q3	–	Sell	-26	Closed	-$212K	–	249
2018 Q2	$61K	Sell	26 -116	-82%	-$738K	0.01%	108
2018 Q1	$209K	Sell	142 -27	-16%	-$155K	0.03%	108
2017 Q4	$251K	Buy	+169	New	+$1.14M	0.04%	90

Other funds holding RDHL

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Altshuler Shaham's RDHL Position: Q1 2023 in Review

Altshuler Shaham sold out of Redhill Biopharma (RDHL) in Q1 2023, closing a stake of 27 shares — an estimated $3.72K sold.

Altshuler Shaham first reported a position in RDHL in Q4 2017 and held it in 4 quarters. The position peaked at $251K in Q4 2017. 16 funds tracked by Wall St. Rank hold RDHL as of Q1 2023.

Altshuler Shaham reported no remaining Redhill Biopharma position as of Q1 2023 after selling out during the quarter.
Altshuler Shaham sold 27 Redhill Biopharma shares in Q1 2023, an estimated $3.72K.
Altshuler Shaham first reported a position in Redhill Biopharma in Q4 2017 and held it in 4 quarters.
Altshuler Shaham's Redhill Biopharma position peaked at $251K in Q4 2017.
16 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2023.

Based on Altshuler Shaham's 13F filing for Q1 2023, filed 9 May 2023.